TrialBMC medicine2026

Camrelizumab plus apatinib for immune checkpoint inhibitor-naive patients with metastatic clear cell renal cell carcinoma after first-line tyrosine kinase inhibitor treatment failure: a single-arm phase 2 trial.

Xiuyu Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.